Literature DB >> 7535723

Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties.

I Gorai1, T Nakazawa, E Miyagi, F Hirahara, Y Nagashima, H Minaguchi.   

Abstract

Two permanent human ovarian clear cell adenocarcinoma lines (OVISE and OVTOKO) were established from metastatic tumors of two patients who were treated with five to six courses of CAP chemotherapy. The two cell lines grow on monolayers and showed a variety in both size and shape: small or moderately sized cuboidal cells, columnar cells, spindle-shaped cells, and malignant tumor giant cells. The cell lines have been in culture for 4 to 6 years, the passage number varying from 160 to 220. The mean population-doubling time of the two cells was 60 to 70 hr. The OVISE cells shed tumor-associated antigens CA19-9, CA125, and TPA in the culture medium, whereas the OVTOKO cells did not secrete them at detectable levels. Immunohistochemical analysis showed that coexpression of cytokeratins and vimentin was preserved in the two cell lines, which is a feature of cultured epithelial origin. Cytokeratin polypeptides 7, 8, 18, and 19 were expressed in both cell lines. The EGF receptor was more intensely expressed in the OVTOKO cells than in the OVISE cells. The estrogen and progesterone receptors were negative in both cell lines. The two cell lines showed no chemosensitivity to anticancer drugs including cisplatin, doxorubicin, cyclophosphamide, and etoposide. Heterotransplantation of the two cell lines reflected the origin of cells. Intraperitoneal transplantation of the OVTOKO cells yielded peritoneal implantation and distant metastasis, whereas that of the OVISE cells showed no dissemination and metastasis. These new ovarian clear cell adenocarcinoma lines will provide a relevant experimental system for further investigations into the intrinsic alterations responsible for malignant progression and chemoresistance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535723     DOI: 10.1006/gyno.1995.1097

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

Review 1.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

2.  Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.

Authors:  Seiya Sato; Hiroaki Itamochi; Nao Oumi; Youhei Chiba; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Chikumi; Michiko Nonaka; Akiko Kudoh; Hiroaki Komatsu; Tasuku Harada; Toru Sugiyama
Journal:  Hum Cell       Date:  2016-03-09       Impact factor: 4.174

3.  ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.

Authors:  Bin Guan; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2011-09-07       Impact factor: 12.701

4.  Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.

Authors:  Bin Guan; Min Gao; Chen-Hsuan Wu; Tian-Li Wang; Ie-Ming Shih
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

5.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Authors:  Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2010-01-15

6.  Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines.

Authors:  Yoshiaki Okuma; Kazushige Kiguchi; Yutaka Koshitaka; Asami Okamura; Isamu Ishiwata; Haruhiro Kondo; Bunpei Ishizuka; Mamoru Tadokoro
Journal:  Hum Cell       Date:  2003-09       Impact factor: 4.174

7.  Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20.

Authors:  T Yanagibashi; I Gorai; T Nakazawa; E Miyagi; F Hirahara; H Kitamura; H Minaguchi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.

Authors:  Satoko Yamaguchi; Yoshiko Maida; Mami Yasukawa; Tomoyasu Kato; Masayuki Yoshida; Kenkichi Masutomi
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

Review 9.  Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer.

Authors:  Hiroshi Kobayashi
Journal:  Reprod Med Biol       Date:  2009-09-26

10.  Establishment and characterization of a cell line (HCH-1) originating from a human clear cell carcinoma of the ovary.

Authors:  Takashi Yamada; Kimiaki Hattori; Hidetoshi Satomi; Tadashi Okazaki; Hiroshi Mori; Yoshinobu Hirose
Journal:  J Ovarian Res       Date:  2016-06-04       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.